Rifaximin and eluxadoline - Newly approved treatments for diarrhea-predominant irritable bowel syndrome: What is their role in clinical practice alongside alosetron?

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 3, 2016, Pages 311-322

  Cash, Brooks D ^a   Lacy, Brian E ^b   Rao, Tharaknath ^c   Earnest, David L ^c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c Prometheus Laboratories Inc   (United States)

Author keywords

5 HT3 receptor antagonist; Adequate relief; Alosetron; Composite endpoint of abdominal pain and stool consistency; Delta opioid receptor (dOR) antagonist; Diarrhea predominant irritable bowel syndrome; Eluxadoline; Mu opioid receptor ( OR) agonist; Non absorbable antibiotic; Rifaximin

Indexed keywords

ALOSETRON; ELUXADOLINE; RIFAXIMIN; ANTIINFECTIVE AGENT; CARBOLINE DERIVATIVE; GASTROINTESTINAL AGENT; IMIDAZOLE DERIVATIVE; NARCOTIC ANTAGONIST; OPIATE RECEPTOR; PHENYLALANINE; RIFAMYCIN; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IRRITABLE COLON; MEDICAL HISTORY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; WELLBEING; AGONISTS; ANALOGS AND DERIVATIVES; DIARRHEA; IRRITABLE BOWEL SYNDROME; PATHOPHYSIOLOGY;

ABDOMINAL PAIN; ANTI-BACTERIAL AGENTS; CARBOLINES; DIARRHEA; GASTROINTESTINAL AGENTS; HUMANS; IMIDAZOLES; IRRITABLE BOWEL SYNDROME; NARCOTIC ANTAGONISTS; PHENYLALANINE; RECEPTORS, OPIOID; RIFAMYCINS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 84957969209     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1118052     Document Type: Review

References (47)

1. Saito YA, Schoenfeld P, Locke 3rd. GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910-1915.
2. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American College of gastroenterology task force on irritable bowel syndrome: an evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl 1):S1-35.
3. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108-2131.
4. Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14:2639-2649.
5. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Dis. 2003;3(Suppl 2):S3-11.
6. Lembo AJ. The clinical and economic burden of irritable bowel syndrome. Pract Gastroenterol. 2007;31(9):3-9 (Suppl).
7. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511.
8. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a US managed care perspective. Am J Gastroenterol. 2003;98:600-607.
9. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736-1741.
10. Ricci J-F, Jhingran P, McLaughlin T, et al. Costs of care for irritable bowel syndrome in managed care. J Clin Outcomes Manag. 2000;7:23-28.
11. Kozma CM, Barghout V, Slaton T, et al. A comparison of office-based physician visits for irritable bowel syndrome and for migraine and asthma. Manag Care Interface. 2002;15:40-43.
12. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848-858.
13. Hungin AP, Molloy-Bland M, Claes R, et al. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care-A Rome Foundation Working Team Report. Aliment Pharmacol Ther. 2014;40:1133-1145.
14. Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100.
15. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol. 2014;20:2482-2491.
16. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503-3506.
17. Boettcher E, Crowe SE. Dietary proteins and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108:728-736.
18. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011;62:381-396.
19. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2-26.
20. Weinberg DS, Smalley W, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1146-1148.
21. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
22. Lembo A, Dove S, Andrae D, et al. Eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome: results of 2 randomized, double-blind, placebocontrolled phase 3 clinical trials of efficacy and safety. Gastroenterology. 2014;146(Suppl 1):S159.
23. Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145:329-338.
24. US Department of Health and Human Services, Food and Drug Administration, News Release, May 27, 2015: [cited 2015 Jun 3]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448328.htm.
25. XIFAXAN (rifaximin) prescribing information. [cited 2014 Aug 15]. Available from: http://cdn.salix.com/shared/pi/xifaxan550-pi.pdf.
26. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136:1979-1988.
27. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24-33.
28. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59:325-332.
29. Salix Investor Day, held 9 July 2014 at the St. Regis Hotel, New York, NY. [cited 2014 Aug 15]. Available from: http://cdn.salix.com/salix/assets/pdf/salix-investor-day.pdf.
30. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, irritable bowel syndrome-clinical evaluation of products for treatment. March 2010. [cited 2014 Dec 12]. Available from: http://www.fdanews.com/ext/resources/files/archives/i/IBS.pdf.
31. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, irritable bowel syndrome-clinical evaluation of drugs for treatment. May 2012. [cited 2014 Dec 12]. Available from: http://www.fda. gov/downloads/Drugs/Guidances/UCM205269.pdf.
32. ClinicalTrials.gov. TARGET 3 trial. [cited 2014 Aug 19]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01543178?term=target+3&rank=1#locn.
33. Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39:1161-1168.
34. Eluxadoline: Digestive Diseases Week presentation, given 6 May 2014. [cited 2014 Sep 20]. Available from: h t t p : //files.shareholder.com/downloads/ABE A-4H9PM3/3215452282x0x752274/f0470ebb-e052-4c0cad29-23093ccbc694/View%20presentation.
35. FujitaW, Gomes I, Dove LS, et al. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heterodimers. Biochem Pharmacol. 2014;92:448-456.
36. Wade P, Palmer J, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed ? opioid receptor agonist/delta opioid receptor antagonist. Br J Pharmacol. 2012;167:1111-1125.
37. Gershon M. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther. 1999;13:15-30.
38. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1998;12:849-855.
39. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104:1831-1843.
40. Nicandro JP, Shin P, Chuang E. Evaluation of treatment continuation with alosetron by IBS-D severity criteria. Curr Med Res Opin. 2012;28:449-456.
41. LOTRONEX (alosetron hydrochloride) prescribing information. [cited 18 Nov 2014]. Available from: https://www.lotronex.com/hcp/-docs/Lotronex-PI.pdf.
42. Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol. 2013;6:344-357.
43. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161:1733-1740.
44. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035-1040.
45. Camilleri M, Krause R, Deveze S, et al. Evaluation of alosetron using the new FDA composite endpoint demonstrates strong treatment effect in females with severe irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2014;109(Suppl 2):S535.
46. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2007;102:1709-1719.
47. Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in womenwith severe diarrhoeapredominant IBS. Aliment Pharmacol Ther. 2012;36:437-448.